November 26, 2025
Source: drugdu
68
Beijing Business News (Reporter Ding Ning) - On the evening of November 25th, Honz Pharmaceutical Co., Ltd. (300086) issued a statement, announcing that recently, the company's "Cough Suppressant Juhong Granules" has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration.
The announcement shows that Cough Suppressant Juhong Granules is a product that the company has already produced and is currently on sale. It was originally a national second-level protected traditional Chinese medicine variety (with a protection period until September 13, 2016), and its current indications are "clearing the lungs, suppressing cough, and resolving phlegm. It is used for cough with excessive phlegm, chest fullness, shortness of breath, dry throat and itchy throat caused by phlegm heat blocking the lungs." Based on the latest clinical research and expert consensus, the company submitted a clinical trial application to add a new indication of "acute exacerbation of chronic obstructive pulmonary disease (phlegm heat blocking the lungs syndrome)" and received the drug clinical trial approval notice.
https://finance.eastmoney.com/a/202511253574356151.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.